Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776149 | 1.00 | CHEK1 (0.45) | CHEK1SLC6A2SLC6A4USP2SMN1; SMN2 | |
| SCHEMBL4146870 | 1.00 | CHEK1 (0.45) | CHEK1SLC6A2SLC6A4USP2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL19692370 | 0.98 | CHEK1 (0.44) | CHEK1SLC6A2SLC6A4USP2SMN1; SMN2 | |
| SCHEMBL15795818 | 0.84 | BRD4 (0.39) | CHEK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27326370 | 0.84 | SLC6A2 (0.51) | CHEK1SLC6A2SLC6A4USP2SMN1; SMN2 | |
| SCHEMBL17866282 | 0.84 | CHEK1 (0.49) | CHEK1SLC6A2SLC6A4USP2SMN1; SMN2 | |
| SCHEMBL16036125 | 0.84 | SLC6A2 (0.51) | CHEK1SLC6A2SLC6A4USP2SMN1; SMN2 | |
| SCHEMBL1501987 | 0.84 | SLC6A2 (0.51) | CHEK1SLC6A2SLC6A4USP2SMN1; SMN2 | |
| SCHEMBL16035265 | 0.83 | USP2 (0.41) | CHEK1SLC6A2SLC6A4USP2SMN1; SMN2 | |
| SCHEMBL28204462 | 0.83 | USP2 (0.41) | CHEK1SLC6A2SLC6A4USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024107434-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11945822-B2 | Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase | QURIENT CO., LTD. (KR) | 2024-04-02 | — | — | US | disclosed |
| WO-2023235384-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023164611-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023028077-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | US | disclosed |
| WO-2003082292-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY AN ARYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082294-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082861-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003076430-A1 | AMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| EP-1324991-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| EP-1324990-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026722-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026723-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | CHEK1 3290/4885SLC6A2 4632/4885SLC6A4 4534/4885 |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | CHEK1 4328/4885SLC6A2 3080/4885SLC6A4 3119/4885 |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | CCR1, MALT1, REL | CHEK1 2736/4885SLC6A2 4087/4885SLC6A4 4570/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | CHEK1 4550/4885SLC6A2 127/4885SLC6A4 175/4885 |
| US-11945822-B2 | Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase | CDK15, CDK1, CDK2 | CHEK1 79/4885SLC6A2 4811/4885SLC6A4 4634/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | CHEK1 3381/4885SLC6A2 4661/4885SLC6A4 4526/4885 |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | TNF, IL1B, IL4 | CHEK1 4874/4885SLC6A2 4758/4885SLC6A4 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.